Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3361-2
Abstract: We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical relapse on PFS in 207 consecutive myeloma patients… read more here.
Keywords: biochemical relapse; prognostic factor; relapse; len dex ... See more keywords
The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy
Sign Up to like & getrecommendations! Published in 2018 at "ecancermedicalscience"
DOI: 10.3332/ecancer.2018.844
Abstract: Introduction The classification of patients with prostate cancer is used to determine treatments based on risk factors. The presence of secondary circulating prostate tumour cells (CPCs) detected in peripheral blood after a curative treatment has… read more here.
Keywords: intermediate risk; risk; biochemical relapse; prostate cancer ... See more keywords